Hemab Therapeutics (COAG) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Mesoblast is the larger company by market cap ($1.79 billion vs $1.44 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COAG | MESO |
|---|---|---|
| Share price | $30.89 | $13.75 |
| Market cap | $1.44B | $1.79B |
| 1-day change | +7.63% | -1.36% |
| YTD return | — | -22.73% |
| 1-year return | — | -22.94% |
| 5-year return | — | +22.71% |
| Forward P/E | — | 30.22 |
| EPS (TTM) | $-4.64 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $17.20M |
| Revenue growth (YoY) | — | +191.39% |
| Net income (latest FY) | — | $-102.14M |
| Gross margin | — | 70.17% |
| Net margin | — | -593.92% |
| 52-week high | $55.42 | $21.50 |
| 52-week low | $23.00 | $13.05 |
| Distance from 52-week high | -44.26% | -36.05% |
| Analyst consensus | none | buy |
| Avg. price target upside | +98.12% | +169.09% |
| Average volume | 458.71K | 232.53K |
| Shares outstanding | 46.71M | 129.85M |
| Employees | 59 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Hemab Therapeutics
COAG stock →Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 59 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
COAG vs MESO FAQ
Which is bigger, Hemab Therapeutics or Mesoblast?
Mesoblast (MESO) is larger, with a market capitalization of $1.79B compared with $1.44B for Hemab Therapeutics (COAG).
Are Hemab Therapeutics and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.